An Open-label Single Ascending Dose and Randomized Double-Masked, Ranibizumab Controlled, Safety, Tolerability, and Efficacy Study of Intravitreal LMG324 in Subjects With Neovascular Age-Related Macular Degeneration
Phase of Trial: Phase I/II
Latest Information Update: 30 Oct 2017
At a glance
- Drugs LMG 324 (Primary) ; Ranibizumab
- Indications Age-related macular degeneration
- Focus First in man; Therapeutic Use
- Sponsors Alcon
- 23 Oct 2017 Status changed from suspended to discontinued based on management decision.
- 13 Jul 2017 Planned End Date changed from 31 Dec 2017 to 1 Sep 2017.
- 04 Jul 2017 Planned End Date changed from 1 May 2017 to 31 Dec 2017.